• Marius Andrei Zavalichi, Ionut Nistor, Alina-Elena Nedelcu, Simona Daniela Zavalichi, Cătălina Marina Arsenescu Georgescu, Cristian Stătescu, and Adrian Covic.
• Cardiovascular Diseases Institute "Prof. Dr. George I.M. Georgescu", "Grigore T. Popa" University of Medicine and Pharmacy, Iasi, Romania.
• Biomed Res Int. 2020 Jan 1; 2020: 6126534.

BackgroundCardiogenic shock is associated with high mortality, despite new strategies for reperfusion therapy. Short-term circulatory support devices may provide adequate support for appropriate myocardial and organ perfusion.ObjectivesThis review is aimed at evaluating the impact on survival when using venoarterial extracorporeal membrane oxygenation (V-A ECMO) in patients with cardiogenic shock due to acute myocardial infarction (AMI).MethodsWe performed a systematic review that included studies using V-A ECMO in patients with cardiogenic shock. Time on ECMO, side effects, and the number of deceased patients, transplanted or upgraded to durable assist devices were analysed. Literature search was done using PubMed/MEDLINE (inception (1969) to January 10, 2019), ProQuest (inception (January 14, 1988) to January 10, 2019), and clinicaltrials.gov (inception (September 12, 2005) to January 10, 2019), by 2 authors. This protocol is registered with PROSPERO (no. CRD42019123982).ResultsWe included 9 studies with a total of 1,998 adult patients receiving V-A ECMO for AMI-induced cardiogenic shock. Survival rate varied from 30.0% to 79.2% at discharge and from 23.2% to 36.1% at 12 months. Time on ECMO varied between 1.96 and 6.0 days. Reported serious adverse events were gastrointestinal bleeding (3.6%) and peripheral complications (8.5%).ConclusionThe use of V-A ECMO among patients with AMI-induced cardiogenic shock may provide survival benefits. However, V-A ECMO treatment effects are inconclusive because of limitations in cohort design and reporting.Copyright © 2020 Marius Andrei Zavalichi et al.

13 keywords...

hide…